Prescribers' satisfaction with delivering medications for opioid use disorder

Hannah K Knudsen, Randy Brown, Nora Jacobson, Julie Horst, Jee-Seon Kim, Hanna Kim, Lynn M Madden, Eric Haram, Todd Molfenter, Hannah K Knudsen, Randy Brown, Nora Jacobson, Julie Horst, Jee-Seon Kim, Hanna Kim, Lynn M Madden, Eric Haram, Todd Molfenter

Abstract

Background: Expanding access to medications for opioid use disorder (MOUD), such as buprenorphine and extended release (XR) naltrexone, is critical to addressing the US opioid epidemic, but little is known about prescriber satisfaction with delivering these two types of MOUD. The current study describes the satisfaction of prescribers delivering buprenorphine and XR-naltrexone while examining whether satisfaction is associated with current patient census and organizational environment.

Methods: As part of a cluster randomized clinical trial (RCT) focused on expanding access to medication for opioid use disorder, 41 MOUD prescribers in Florida, Ohio, and Wisconsin completed a web-based survey. The survey included measures of prescriber satisfaction with delivering buprenorphine treatment and XR-naltrexone. In addition, the survey measured several prescriber characteristics and their perceptions of the organizational environment.

Results: Prescribers were generally satisfied with their work in delivering these two types of MOUD. Prescribers reporting a greater number of patients (r = .46, p = .006), those who would recommend the center to others (r = .56, p < .001), and those reporting positive relationships with staff (r = .56, p < .001) reported significantly greater overall satisfaction with delivering buprenorphine treatment. Prescribers who more strongly endorsed feeling overburdened reported lower overall buprenorphine satisfaction (r = -.37, p = .02). None of the prescriber characteristics or perceptions of the organizational environment were significantly associated with overall satisfaction with delivering XR-naltrexone treatment.

Conclusions: The generally high levels of satisfaction with both types of MOUD is notable given that prescriber dissatisfaction can lead to turnover and impact intentions to leave the profession. Future research should continue to explore the prescriber characteristics and organizational factors associated with satisfaction in providing different types of MOUD.

Registration: ClinicalTrials.gov. NCT02926482. Date of registration: September 9, 2016. https://ichgcp.net/clinical-trials-registry/NCT02926482 .

Keywords: buprenorphine; extended-release naltrexone; opioid use disorder; prescriber satisfaction.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

References

    1. Wilson N, Kariisa M, Seth P, Smith Ht, Davis NL. Drug and opioid-involved overdose deaths - United States, 2017-2018. MMWR Morb Mortal Wkly Rep. 2020;69:290–7. doi: 10.15585/mmwr.mm6911a4.
    1. Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: Opioid use disorder and COVID-19. Ann Intern Med. 2020;173:57–8. doi: 10.7326/M20-1141.
    1. Wainwright JJ, Mikre M, Whitley P, Dawson E, Huskey A, Lukowiak A, et al. Analysis of drug test results before and after the us declaration of a national emergency concerning the COVID-19 outbreak. JAMA. 2020.
    1. Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020;214:108176. doi: 10.1016/j.drugalcdep.2020.108176.
    1. American Society of Addiction Medicine . The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioids Chevy Chase. MD: ASAM; 2015.
    1. Substance Abuse and Mental Health Services Administration . Medications for opioid use disorder (Treatment Improvement Protocol (TIP) Series 63) Rockville: SAMHSA; 2018.
    1. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies--Tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063–6. doi: 10.1056/NEJMp1402780.
    1. Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377:391–4. doi: 10.1056/NEJMsr1706626.
    1. Volkow ND. Medications for opioid use disorder: bridging the gap in care. Lancet. 2018;391:285–7. doi: 10.1016/S0140-6736(17)32893-3.
    1. Dick AW, Pacula RL, Gordon AJ, Sorbero M, Burns RM, Leslie D, et al. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11. Health Aff. 2015;34:1028–34. doi: 10.1377/hlthaff.2014.1205.
    1. Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. J Rural Health. 2019;35:108–12. doi: 10.1111/jrh.12307.
    1. Knudsen HK, Lin LA, Lofwall MR. Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: A state-level longitudinal analysis. Subst Abus. 2020;41:259–68. doi: 10.1080/08897077.2019.1635959.
    1. Auty SG, Stein MD, Walley AY, Drainoni ML. Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply. J Subst Abuse Treat. 2020;115:108032. doi: 10.1016/j.jsat.2020.108032.
    1. Duncan A, Anderman J, Deseran T, Reynolds I, Stein BD. Monthly patient volumes of buprenorphine-waivered clinicians in the US. JAMA Netw Open. 2020;3:e2014045. doi: 10.1001/jamanetworkopen.2020.14045.
    1. Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–6. doi: 10.1016/j.jsat.2017.07.001.
    1. Boudreau DM, Lapham G, Johnson EA, Bobb JF, Matthews AG, McCormack J, et al. Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems. J Subst Abuse Treat. 2020;112S:41–8. doi: 10.1016/j.jsat.2020.02.001.
    1. Becker WC, Fiellin DA. Provider satisfaction with office-based treatment of opioid dependence: a systematic review. Subst Abus. 2005;26:15–22. doi: 10.1300/J465v26n01_02.
    1. Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: Recommendations from rural physicians. J Rural Health. 2019;35:113–21. doi: 10.1111/jrh.12328.
    1. Knudsen HK, Brown R, Jacobson N, Horst J, Kim JS, Collier E, et al. Physicians’ satisfaction with providing buprenorphine treatment. Addict Sci Clin Pract. 2019;14:34. doi: 10.1186/s13722-019-0163-3.
    1. Williams ES, Skinner AC. Outcomes of physician job satisfaction: a narrative review, implications, and directions for future research. Health Care Manage Rev. 2003;28:119–39. doi: 10.1097/00004010-200304000-00004.
    1. Sinsky CA, Dyrbye LN, West CP, Satele D, Tutty M, Shanafelt TD. Professional satisfaction and the career plans of US physicians. Mayo Clin Proc. 2017;92:1625–35.
    1. Williams ES, Konrad TR, Scheckler WE, Pathman DE, Linzer M, McMurray JE, et al. Understanding physicians’ intentions to withdraw from practice: the role of job satisfaction, job stress, mental and physical health. Health Care Manage Rev. 2001;26:7–19. doi: 10.1097/00004010-200101000-00002.
    1. Linn LS, Brook RH, Clark VA, Davies AR, Fink A, Kosecoff J. Physician and patient satisfaction as factors related to the organization of internal medicine group practices. Med Care. 1985;23:1171–8. doi: 10.1097/00005650-198510000-00006.
    1. Haas JS, Cook EF, Puopolo AL, Burstin HR, Cleary PD, Brennan TA. Is the professional satisfaction of general internists associated with patient satisfaction? J Gen Intern Med. 2000;15:122–8. doi: 10.1046/j.1525-1497.2000.02219.x.
    1. DiMatteo MR, Sherbourne CD, Hays RD, Ordway L, Kravitz RL, McGlynn EA, et al. Physicians’ characteristics influence patients’ adherence to medical treatment: results from the Medical Outcomes Study. Health Psychol. 1993;12:93–102. doi: 10.1037/0278-6133.12.2.93.
    1. Lee JD, Nunes EV, Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391:309–18. doi: 10.1016/S0140-6736(17)32812-X.
    1. Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113:1188–209. doi: 10.1111/add.14180.
    1. Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. 2019;200:34–9. doi: 10.1016/j.drugalcdep.2019.02.031.
    1. Hall CB, Brazil K, Wakefield D, Lerer T, Tennen H. Organizational culture, job satisfaction, and clinician turnover in primary care. J Prim Care Community Health. 2010;1:29–36. doi: 10.1177/2150131909360990.
    1. McMurray JE, Williams E, Schwartz MD, Douglas J, Van Kirk J, Konrad TR, et al. Physician job satisfaction: developing a model using qualitative data. SGIM Career Satisfaction Study Group. J Gen Intern Med. 1997;12:711–4. doi: 10.1046/j.1525-1497.1997.07145.x.
    1. Linzer M, Sinsky CA, Poplau S, Brown R, Williams E. Healthy Work Place I. Joy in medical practice: Clinician satisfaction in the Healthy Work Place Trial. Health Aff (Millwood) 2017;36:1808–14. doi: 10.1377/hlthaff.2017.0790.
    1. Molfenter T, Knudsen H, Brown R, Jacobsen N, Horst J, Van Etten M, et al. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: Protocol for a cluster-randomized trial. Implement Sci. 2017;12:135. 10.1186/s13012-017-0665-x.
    1. Williams ES, Konrad TR, Linzer M, McMurray J, Pathman DE, Gerrity M, et al. Refining the measurement of physician job satisfaction: results from the Physician Worklife Survey. SGIM Career Satisfaction Study Group. Society of General Internal Medicine. Med Care. 1999;37:1140–54. doi: 10.1097/00005650-199911000-00006.
    1. Miller J. Workforce survey 2018. Behavioral Healthcare Executive 2018: Available from: .
    1. Shanafelt TD, Boone S, Tan L, Dyrbye LN, Sotile W, Satele D, et al. Burnout and satisfaction with work-life balance among US physicians relative to the general US population. Arch Intern Med. 2012;172:1377–85. doi: 10.1001/archinternmed.2012.3199.
    1. Cohen J. A power primer. Psychol Bull. 1992;112:155–9. doi: 10.1037/0033-2909.112.1.155.
    1. Chowdhury MM, Dagash H, Pierro A. A systematic review of the impact of volume of surgery and specialization on patient outcome. Br J Surg. 2007;94:145–61. doi: 10.1002/bjs.5714.
    1. Morche J, Mathes T, Pieper D. Relationship between surgeon volume and outcomes: a systematic review of systematic reviews. Syst Rev. 2016;5:204. doi: 10.1186/s13643-016-0376-4.
    1. Jacobson N, Horst J, Wilcox-Warren L, Toy A, Knudsen HK, Brown R, et al. Organizational facilitators and barriers to medication for opioid use disorder capacity expansion and use. J Behav Health Serv Res. 2020;47:439–48. doi: 10.1007/s11414-020-09706-4.
    1. Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1–7. doi: 10.1016/j.jsat.2017.04.005.
    1. Kermack A, Flannery M, Tofighi B, McNeely J, Lee JD. Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abuse Treat. 2017;74:1–6. doi: 10.1016/j.jsat.2016.10.005.
    1. Thomas CP, Doyle E, Kreiner PW, Jones CM, Dubenitz J, Horan A, et al. Prescribing patterns of buprenorphine waivered physicians. Drug Alcohol Depend. 2017;181:213–8. doi: 10.1016/j.drugalcdep.2017.10.002.
    1. Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316:1211–2. doi: 10.1001/jama.2016.10542.
    1. Andrilla CHA, Coulthard C, Patterson DG. Prescribing practices of rural physicians waivered to prescribe buprenorphine. Am J Prev Med. 2018;54:208-S14.
    1. Stein BD, Saloner B, Schuler MS, Gurvey J, Sorbero M, Gordon AJ. Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US. JAMA. 2021;325:2206–8. doi: 10.1001/jama.2021.4469.
    1. Stein BD, Gordon AJ, Dick AW, Burns RM, Pacula RL, Farmer CM, et al. Supply of buprenorphine waivered physicians: The influence of state policies. J Subst Abuse Treat. 2015;48:104–11. doi: 10.1016/j.jsat.2014.07.010.
    1. Knudsen HK, Havens JR, Lofwall MR, Studts JL, Walsh SL. Buprenorphine physician supply: Relationship with state-level prescription opioid mortality. Drug Alcohol Depend. 2017;173(Suppl 1):55–64. doi: 10.1016/j.drugalcdep.2016.08.642.
    1. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105:e55–63. doi: 10.2105/AJPH.2015.302664.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅